In recent discussions, Dr. Phillip Kuo addressed the appropriate use criteria for amyloid and tau PET imaging in patients with mild cognitive impairment (MCI). He emphasized that while amyloid PET is essential for diagnosing Alzheimer's disease, it alone is insufficient. Dr. Kuo illustrated this point with case studies, revealing that different patients exhibited similar amyloid PET scans despite varying disease stages. Consequently, he underscored the importance of combining amyloid PET with tau PET for a comprehensive understanding of the disease's neuropathology. In other news, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) has updated its guidelines for the use of amyloid and tau PET imaging. Additionally, new research involving over 2,200 women indicated that those with high scores on the CORSWO model face a fourfold increase in the risk of major adverse coronary events (MACE). A study also revealed discrepancies in follow-up imaging agreement between radiologists and referring clinicians, with thoracic radiologists providing more likely recommendations. Furthermore, newly published guidelines detail the use of imaging modalities for peritoneal metastases in ovarian and colorectal cancers. A new SPECT/CT scanner designed for theranostic applications was launched at the European Association of Nuclear Medicine meeting, and the FDA has cleared new tools for standardized assessment of amyloid plaques and tau protein tangles, which may aid in Alzheimer's diagnosis.
Fri, 17 Jan 2025 20:55:44 GMT | Diagnostic Imaging